P. Riederer, H. Reichmann,
M. B. H. Youdim, M. Gerlach (eds.)

Parkinson’s Disease and Related Disorders

Journal of Neural Transmission
Supplement 70

SpringerWienNewYork
Preface

It is our pleasure to present the Proceedings of the 16th International Congress on Parkinson’s Disease (PD) and Related Disorders (16th ICPD) which took place in Berlin from June 5–9, 2005. This congress was the most successful congress ever with more than 3500 participants in the roaring German capital, consisting of an innovative program and with emphasis on bringing basic and clinical scientists together. Special attention has was paid in inviting young scientists. Therefore, the major aspect of scientific sessions was to identify young and up coming individuals in the field, with novel approaches to PD and novel models as a whole. The congress gave us the opportunity to present Germany and its capital after the burden of recent history in the new light of a reunified and peaceful country. We have succeeded in presenting the country as an important part of Europe and as a country of arts, architecture and renewal. The Congress attracted new friends from more than 75 countries worldwide.

For this reason, we are most thankful to the World Federation of Neurology (WFN), Research Group on Parkinsonism and Related Disorders (RGPD), chaired by Professor Donald Calne for bringing this congress to Germany!

The Congress had many highlights with lectures covering all the major fields in PD and Related Disorders. The opening ceremony was highlighted by the inspiring presentation of Nobel Laureate Paul Greengard who lectured on dopamine-related signalling pathways in the brain, followed by the welcome addresses by Professor Riederer, President of the 16th ICPD, Professor Calne, President of the WFN-RGPD, Dr. Slewett, President emeritus of the National Parkinson Foundation, Miami, USA (NPF), Professor Kimura, President WFN, Professor Reichmann, President German Parkinson Society and Professor Einhäupl, Chairman of the Germany Science Council. The speeches were followed by a musical interlude of the “Sunday Night Orchestra” and the award ceremony of the WFN Research Committee on Parkinsonism and Related Disorders. The welcome reception presented typical German dishes and drinks.

In total the congress included 4 plenary lectures, 20 symposia, 6 hot topics, 4 video sessions, 1 workshop with demonstration, 29 educational seminars, more than 600 posters which were presented throughout the congress, 44 guided poster tours, 4 poster symposia, and 14 satellite symposia.

There were many scientific highlights and this proceeding intends to give a representative overview of congress programme. In this preface we are only able to give a glimpse of the outstanding lectures and scientific events during the 5 days.

The congress started with a satellite symposium on the significance of neuromelanin in the human brain. This symposium was dedicated to Prof. Youdim on the occasion of his 65th birthday. These contributions are published separately in a Special Issue of the Journal of Neural Transmission. Professor Carlsson, 2000 Nobel Laureate, spent significant time at the congress site and was often seen discussing topics of mutual interest with congress participant’s. There was an interesting new study presented by Professor Deuschl, Kiel, in which he demonstrates that deep brain stimulation results in even better outcome of motor function than regular medication. For this reason, he advocated earlier use of deep brain stimulation in PD. New medications were discussed in detail both in the plenary lectures and satellites and new drugs such as rasagiline, the new MAO-B-inhibitor and rotigotine, the new dermal patch, were discussed in detail. There were satellite meetings on apomorphine, COMT-inhibitors, levodopa, sphaeramine (a new promising cell therapy for the treatment of PD in the advanced stage), dopamine transporter scanning, dopamine agonists such as pramipexole, ropinirole and cabergoline, adenosine antagonists, restless legs, deep brain stimulation, botulinum toxin A, and the new lisuride dermal patch. All satellites were of highest quality and delivered valuable insights in present and new therapy of PD.

Special lectures addressed the advent of gene therapy and stem cell therapy, although it is apparent that there is still a long way to go until this therapy can be safe and affordable for many PD patients longing for disease modifying treatment.
Professors Schapira and Olanow gave an overview on the ever contradictory aspects of neuroprotection. While neuroprotection is generally accepted in animal models and cell culture, there is still discussion on whether SPECT- and PET-analyses and the delayed start design, as employed in the rasagiline study indicated neuroprotection in man. For neuroprotection to be successful earlier diagnosis of PD is mandatory. For this reason, groups from Amsterdam, Dresden, Tübingen and Würzburg are working on early diagnosis procedures such as olfactory tests, parenchymal sonography, REM sleep analyses, and biochemical markers.

There were lectures on treatment of PD and many on genetic abnormalities causing PD, mitochondrial abnormalities and other disturbances of cell function which lead to dopaminergic cell death.

The other major aspect of the scientific session was the field of basic neuroscience to illuminate our current understanding of how neurons die in sporadic and familial PD. This included symposia on development of midbrain dopaminergic neurons, the role of iron in neurodegeneration, and the progress on genetics and proteomics and the concept of developing novel multifunctional neuroprotective drugs for such a complex disease.

Twenty nine educational seminars covered the most important topics and problems in clinical science bringing theory to practice and treatment strategies.

The guided poster tours allowed exchange of scientific ideas and shed light on new findings in etiology, diagnosis and treatment of PD and related disorders.

A special highlight of the Congress was the Art Exhibition, demonstrating the creativity of our patients with movement disorders. This exhibition was organized by the German Parkinson’s lay organisation as well as by the Austrian lay organisation. Professor Maurer, Frankfurt, presented Art from an Alzheimer’s patient, the Carolus Horn Exhibition, which impressively demonstrated change in the way to paint during a dementive process.

Another highlight was the Medical Historical Exhibition which was organised by Dr. Ch. Riederer, Würzburg, which focused on the history of the treatment of PD and emphasized the Berlin contributions by H. Lewy, W. v. Humboldt, R. Hassler and others.

A special tribute was paid to Melvin Yahr who sadly passed away in early 2005 shortly before this Congress. He was greatly missed.

Due to generous educational grants from the industry the organizers were able to honour outstanding scientists and clinicians, Toshiharu Nagatsu, Yoshikuni Mizuno, Japan (Award of the WFN Research Group on Parkinsonism and Related Disorders), Saskia Biskup, Germany and Andrew B. Singleton, USA (16th ICPD Junior Research Award), Jonathan Brodie, Canada and Alan Crossman, UK (Merck KGaA Dyskinesia Research Award). GE Healthcare sponsored the 16th ICPD Senior Researcher Award given to Silvia Mandel, Israel and Vincenzo Bonifati, The Netherlands. Both companies gave educational grants for the 12 Poster Prizes while the Melvin Yahr Foundation sponsored 26 Fellowships. In addition the congress made it possible to bring numerous young scientists to the congress by giving them financial support for travelling and accommodation.

The Senator Dr. Franz Burda Award presented by Helmut Lechner, Austria, and Franz Gerstenbrand, was given to Laszlo Vecsei, Hungary and Tino Battistin, Italy.

We thank all the participants who gave us their creative input to organize a World Congress on PD (as indicated in the First Announcement) which fulfilled the criteria of excellence and made the congress so successful. This was YOUR congress and which many of you influenced by letting us know your wishes and expectations. New concepts, formats and innovations, the active and constructive cooperation by the participating industry and the lay organisations made all this possible. This can measured by the numerous complimentary letters and emails we have received since then and we hope it sets the standards for future meetings! By doing all this we tried to come close to our milestone “Present and Future Perspectives of Parkinson’s Syndrome”.

Our special thanks go to CPO Hanser Congress Organisation, the programme committee and the WFN Research Group which all worked so hard to make this Congress so successful.

Finally the congress proceedings are published and we thank all those who contributed to this volume. Special thanks go to Springer Verlag, Vienna, New York for their efficient and splendid ability in being able to publish the proceeding so rapidly.

Peter Franz Riederer, Heinz Reichmann, Moussa Youdim, Manfred Gerlach
Würzburg, Dresden, Haifa, spring 2006
# Contents

**Powell, C.**: Melvin Yahr (1917–2004). An appreciation ........................................... 1  

## 1. Pathology

**Hornykiewicz, O.**: The discovery of dopamine deficiency  
in the parkinsonian brain ................................................................. 9  
**Heimer, G., Rivlin, M., Israel, Z., Bergman, H.**: Synchronizing activity  
of basal ganglia and pathophysiology of Parkinson’s disease ............................. 17  
**Wichmann, T., DeLong, M. R.**: Basal ganglia discharge abnormalities  
in Parkinson’s disease ......................................................................... 21  
**Brown, P.**: Bad oscillations in Parkinson’s disease ........................................ 27  
**McKeown, M. J., Palmer, S. J., Au, W.-L., McCaig, R. G.,  
Saab, R., Abu-Gharbieh, R.**: Cortical muscle coupling in Parkinson’s disease  
(PD) bradykinesia .............................................................................. 31  
**Burke, R. E.**: GDNF as a candidate striatal target-derived neurotrophic  
factor for the development of substantia nigra dopamine neurons .................... 41  
**Gherbassi, D., Simon, H. H.**: The engrailed transcription factors  
and the mesencephalic dopaminergic neurons .............................................. 47  
**Smits, S. M., Smidt, M. P.**: The role of Pitx3 in survival of midbrain  
dopaminergic neurons .......................................................................... 57  
**Ryu, S., Holzschuh, J., Mahler, J., Driever, W.**: Genetic analysis of dopaminergic  
system development in zebrafish ...................................................... 61  
**Deutch, A. Y.**: Striatal plasticity in parkinsonism: dystrophic changes  
in medium spiny neurons and progression in Parkinson’s disease .................... 67  
**Fuxe, K., Manger, P., Genedani, S., Agnati, L.**: The nigrostriatal DA pathway  
and Parkinson’s disease ....................................................................... 71  
**Parent, M., Parent, A.**: Relationship between axonal collateralization  
and neuronal degeneration in basal ganglia ............................................. 85  
**Braak, H., Müller, C. M., Rüb, U., Ackermann, H., Bratzke, H.,  
de Vos, R. A. I., Del Tredici, K.**: Pathology associated with sporadic  
Parkinson’s disease – where does it end? ............................................. 89  
**Halliday, G. M., Del Tredici, K., Braak, H.**: Critical appraisal of brain  
pathology staging related to presymptomatic and symptomatic cases  
of sporadic Parkinson’s disease ........................................................... 99  
**Giorgi, F. S., Bandettini di Poggio, A., Battaglia, G., Pellegrini, A.,  
Murri, L., Ruggieri, S., Paparelli, A., Fornai, F.**: A short overview  
on the role of α-synuclein and proteasome in experimental models  
of Parkinson’s disease ........................................................................ 105  
**Gispert-Sanchez, S., Auburger, G.**: The role of protein aggregates  
in neuronal pathology: guilty, innocent, or just trying to help? ................. 111
2. Iron and neuromelanin

Maruyama, W., Shamoto-Nagai, M., Akao, Y., Riederer, P., Naoi, M.:  
The effect of neuromelanin on the proteasome activity in human  
dopaminergic SH-SY5Y cells ........................................ 125
Gerlach, M., Double, K. L., Youdim, M. B. H., Riederer, P.:  
Potential sources of increased iron in the substantia nigra  
of parkinsonian patients ............................................ 133
Pandolfo, M.: Iron and Friedreich ataxia. ...................................... 143

3. Genetics

Chade, A. R., Kasten, M., Tanner, C. M.: Nongenetic causes  
of Parkinson’s disease .................................................. 147
Lannuzel, A., Höglinger, G. U., Champy, P., Michel, P. P.,  
Hirsch, E. C., Ruberg, M.: Is atypical parkinsonism in the Caribbean  
caused by the consumption of Annonaceae? ............................... 153
Mellick, G. D.: CYP450, genetics and Parkinson’s disease:  
gene×environment interactions hold the key ................................ 159
Ravindranath, V., Kommadadi, R. P., Pai, H. V.: Unique cytochromes  
P450 in human brain: implication in disease pathogenesis .................. 167
Viaggi, C., Pardini, C., Vaglini, F., Corsini, G. U.: Cytochrome P450  
and Parkinson’s disease: protective role of neuronal CYP 2E1  
from MPTP toxicity ..................................................... 173
Miksys, S., Tyndale, R. F.: Nicotine induces brain CYP enzymes:  
relevance to Parkinson’s disease ...................................... 177
Riess, O., Krüger, R., Hochstrasser, H., Soehn, A. S., Nuber, S.,  
Franck, T., Berg, D.: Genetic causes of Parkinson’s disease:  
extending the pathway ...................................................... 181
Mizuno, Y., Hattori, N., Yoshino, H., Hatano, Y., Satoh, K.,  
Tomiyama, H., Li, Y.: Progress in familial Parkinson’s disease ................. 191
Hattori, N., Machida, Y., Sato, S., Noda, K., Iijima-Kitami, M.,  
Kubo, S., Mizuno, Y.: Molecular mechanisms of nigral neurodegeneration  
in Park2 and regulation of parkin protein by other proteins ..................... 205
Dawson, T. M.: Parkin and defective ubiquitination in Parkinson’s disease .......... 209
Heutink, P.: PINK-1 and DJ-1 – new genes for autosomal recessive  
Parkinson’s disease ...................................................... 215
Whaley, N. R., Uinti, R. J., Dickson, D. W., Farrer, M. J., Wszolek, Z. K.:  
Clinical and pathologic features of families with LRRK2-associated  
Parkinson’s disease ...................................................... 221
Gasser, T.: Molecular genetic findings in LRRK2 American, Canadian  
and German families ................................................... 231

4. Imaging

Lu, C.-S., Wu Chou, Y.-H., Weng, Y.-H., Chen, R.-S.: Genetic and DAT  
imaging studies of familial parkinsonism in a Taiwanese cohort ................. 235
Lok Au, W., Adams, J. R., Troiano, A., Stoessl, A. J.:  
Neuroimaging in Parkinson’s disease .................................... 241
Berg, D.: Transcranial sonography in the early and differential diagnosis  
of Parkinson’s disease .................................................. 249
5. Models

Hirsch, E. C.: How to judge animal models of Parkinson’s disease in terms of neuroprotection .................................................. 255
Falkenburger, B. H., Schulz, J. B.: Limitations of cellular models in Parkinson’s disease research ........................................... 261
Mochizuki, H., Yamada, M., Mizuno, Y.: α-Synuclein overexpression model ........................................ 281

6. Clinical approaches

Goetz, C. G.: What’s new? Clinical progression and staging of Parkinson’s disease .. 305
Wolters, E. Ch., Braak, H.: Parkinson’s disease: premotor clinico-pathological correlations ........................................... 309
Berendse, H. W., Ponsen, M. M.: Detection of preclinical Parkinson’s disease along the olfactory tract(t) ........................................... 321
Giladi, N., Balash, Y.: The clinical approach to gait disturbances in Parkinson’s disease; maintaining independent mobility ........................................... 327
Bodis-Wollner, I., Jo, M.-Y.: Getting around and communicating with the environment: visual cognition and language in Parkinson’s disease .................................. 333
Goldstein, D. S.: Cardiovascular aspects of Parkinson disease ........................................... 339
Mathias, C. J.: Multiple system atrophy and autonomic failure ........................................... 343
Comella, C. L.: Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview ........................................... 349
Arnulf, I.: Sleep and wakefulness disturbances in Parkinson’s disease .............. 357

7. Neuroinflammation

Burn, D. J.: Parkinson’s disease dementia: what’s in a Lewy body? ........................................... 361
Qian, L., Hong, J.-S., Flood, P. M.: Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of Interleukin 10 ........................................... 367
Sawada, M., Imamura, K., Nagatsu, T.: Role of cytokines in inflammatory process in Parkinson’s disease ........................................... 373

8. Neurosurgery

9. L-Dopa

de la Fuente-Fernández, R., Lidstone, S., Stoessl, A. J.: Placebo effect and dopamine release .............................................. 415
Fahn, S.: A new look at levodopa based on the ELLDOPA study ............................... 419

10. Neuroprotection

Uitti, R. J., Wszolek, Z. K.: Concerning neuroprotective therapy for Parkinson’s disease .............................................. 433
Zigmond, M. J.: Triggering endogenous neuroprotective mechanisms in Parkinson’s disease: studies with a cellular model .............................................. 439
Weinstock, M., Luques, L., Bejar, C., Shoham, S.: Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression ................................. 443
Weinreb, O., Amit, T., Bar-Am, O., Sagi, Y., Mandel, S., Youdim, M. B. H.: Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety .............................................. 457

11. Other treatment strategies

Schulz, J. B.: Anti-apoptotic gene therapy in Parkinson’s disease .............................................. 467
Kaufmann, H.: The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors .............................................. 477

12. Dystonia

Hallett, M.: Pathophysiology of dystonia .............................................. 485
Bressman, S.: Genetics of dystonia .............................................. 489

Index .............................................. 497

Listed in Current Contents/Life Sciences